Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer
Identifieur interne : 001181 ( Main/Exploration ); précédent : 001180; suivant : 001182Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer
Auteurs : Katherine Reeder-Hayes [États-Unis] ; Sharon Peacock Hinton [États-Unis] ; Ke Meng [États-Unis] ; Lisa A. Carey [États-Unis] ; Stacie B. Dusetzina [États-Unis]Source :
- Journal of Clinical Oncology [ 0732-183X ] ; 2016.
Abstract
Trastuzumab is a key component of adjuvant therapy for stage I to III human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The rates and patterns of trastuzumab use have never been described in a population-based sample. The recent addition of HER2 information to the SEER-Medicare database offers an opportunity to examine patterns of trastuzumab use and to evaluate possible disparities in receipt of trastuzumab.
We examined a national cohort of Medicare beneficiaries with incident stage I to III HER2-positive breast cancer diagnosed in 2010 and 2011 (n = 1,362). We used insurance claims data to track any use of trastuzumab in the 12 months after diagnosis as well as to identify chemotherapy drugs used in partnership with trastuzumab. We used modified Poisson regression analysis to evaluate the independent effect of race on likelihood of receiving trastuzumab by controlling for clinical need, comorbidity, and community-level socioeconomic status.
Overall, 50% of white women and 40% of black women received some trastuzumab therapy. Among women with stage III disease, 74% of whites and 56% of blacks received trastuzumab. After adjustment for tumor characteristics, poverty, and comorbidity, black women were 25% less likely to receive trastuzumab within 1 year of diagnosis than white women (risk ratio, 0.745; 95% CI, 0.60 to 0.93).
Approxemately one half of patients 65 years of age and older with stage I to III breast cancer do not receive trastuzumab-based therapy, which includes many with locally advanced disease. Significant racial disparities exist in the receipt of this highly effective therapy. Further research that identifies barriers to use and increases uptake of trastuzumab could potentially improve recurrence and survival outcomes in this population, particularly among minority women.
Url:
DOI: 10.1200/JCO.2015.65.8716
PubMed: 27069085
PubMed Central: 4966516
Affiliations:
- États-Unis
- Caroline du Nord
- Chapel Hill (Caroline du Nord)
- Université de Caroline du Nord à Chapel Hill
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000682
- to stream Pmc, to step Curation: 000682
- to stream Pmc, to step Checkpoint: 000A49
- to stream Ncbi, to step Merge: 008162
- to stream Ncbi, to step Curation: 008162
- to stream Ncbi, to step Checkpoint: 008162
- to stream Main, to step Merge: 001183
- to stream Main, to step Curation: 001181
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer</title>
<author><name sortKey="Reeder Hayes, Katherine" sort="Reeder Hayes, Katherine" uniqKey="Reeder Hayes K" first="Katherine" last="Reeder-Hayes">Katherine Reeder-Hayes</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peacock Hinton, Sharon" sort="Peacock Hinton, Sharon" uniqKey="Peacock Hinton S" first="Sharon" last="Peacock Hinton">Sharon Peacock Hinton</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meng, Ke" sort="Meng, Ke" uniqKey="Meng K" first="Ke" last="Meng">Ke Meng</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carey, Lisa A" sort="Carey, Lisa A" uniqKey="Carey L" first="Lisa A." last="Carey">Lisa A. Carey</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dusetzina, Stacie B" sort="Dusetzina, Stacie B" uniqKey="Dusetzina S" first="Stacie B." last="Dusetzina">Stacie B. Dusetzina</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">27069085</idno>
<idno type="pmc">4966516</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966516</idno>
<idno type="RBID">PMC:4966516</idno>
<idno type="doi">10.1200/JCO.2015.65.8716</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000682</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000682</idno>
<idno type="wicri:Area/Pmc/Curation">000682</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000682</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000A49</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A49</idno>
<idno type="wicri:Area/Ncbi/Merge">008162</idno>
<idno type="wicri:Area/Ncbi/Curation">008162</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">008162</idno>
<idno type="wicri:doubleKey">0732-183X:2016:Reeder Hayes K:disparities:in:use</idno>
<idno type="wicri:Area/Main/Merge">001183</idno>
<idno type="wicri:Area/Main/Curation">001181</idno>
<idno type="wicri:Area/Main/Exploration">001181</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer</title>
<author><name sortKey="Reeder Hayes, Katherine" sort="Reeder Hayes, Katherine" uniqKey="Reeder Hayes K" first="Katherine" last="Reeder-Hayes">Katherine Reeder-Hayes</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peacock Hinton, Sharon" sort="Peacock Hinton, Sharon" uniqKey="Peacock Hinton S" first="Sharon" last="Peacock Hinton">Sharon Peacock Hinton</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meng, Ke" sort="Meng, Ke" uniqKey="Meng K" first="Ke" last="Meng">Ke Meng</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Carey, Lisa A" sort="Carey, Lisa A" uniqKey="Carey L" first="Lisa A." last="Carey">Lisa A. Carey</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dusetzina, Stacie B" sort="Dusetzina, Stacie B" uniqKey="Dusetzina S" first="Stacie B." last="Dusetzina">Stacie B. Dusetzina</name>
<affiliation wicri:level="4"><nlm:aff id="aff1">All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.</nlm:aff>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
<country>États-Unis</country>
<placeName><settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
<region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Clinical Oncology</title>
<idno type="ISSN">0732-183X</idno>
<idno type="eISSN">1527-7755</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Purpose</title>
<p>Trastuzumab is a key component of adjuvant therapy for stage I to III human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The rates and patterns of trastuzumab use have never been described in a population-based sample. The recent addition of HER2 information to the SEER-Medicare database offers an opportunity to examine patterns of trastuzumab use and to evaluate possible disparities in receipt of trastuzumab.</p>
</sec>
<sec><title>Methods</title>
<p>We examined a national cohort of Medicare beneficiaries with incident stage I to III HER2-positive breast cancer diagnosed in 2010 and 2011 (n = 1,362). We used insurance claims data to track any use of trastuzumab in the 12 months after diagnosis as well as to identify chemotherapy drugs used in partnership with trastuzumab. We used modified Poisson regression analysis to evaluate the independent effect of race on likelihood of receiving trastuzumab by controlling for clinical need, comorbidity, and community-level socioeconomic status.</p>
</sec>
<sec><title>Results</title>
<p>Overall, 50% of white women and 40% of black women received some trastuzumab therapy. Among women with stage III disease, 74% of whites and 56% of blacks received trastuzumab. After adjustment for tumor characteristics, poverty, and comorbidity, black women were 25% less likely to receive trastuzumab within 1 year of diagnosis than white women (risk ratio, 0.745; 95% CI, 0.60 to 0.93).</p>
</sec>
<sec><title>Conclusion</title>
<p>Approxemately one half of patients 65 years of age and older with stage I to III breast cancer do not receive trastuzumab-based therapy, which includes many with locally advanced disease. Significant racial disparities exist in the receipt of this highly effective therapy. Further research that identifies barriers to use and increases uptake of trastuzumab could potentially improve recurrence and survival outcomes in this population, particularly among minority women.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
</region>
<settlement><li>Chapel Hill (Caroline du Nord)</li>
</settlement>
<orgName><li>Université de Caroline du Nord à Chapel Hill</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Reeder Hayes, Katherine" sort="Reeder Hayes, Katherine" uniqKey="Reeder Hayes K" first="Katherine" last="Reeder-Hayes">Katherine Reeder-Hayes</name>
</region>
<name sortKey="Carey, Lisa A" sort="Carey, Lisa A" uniqKey="Carey L" first="Lisa A." last="Carey">Lisa A. Carey</name>
<name sortKey="Dusetzina, Stacie B" sort="Dusetzina, Stacie B" uniqKey="Dusetzina S" first="Stacie B." last="Dusetzina">Stacie B. Dusetzina</name>
<name sortKey="Meng, Ke" sort="Meng, Ke" uniqKey="Meng K" first="Ke" last="Meng">Ke Meng</name>
<name sortKey="Peacock Hinton, Sharon" sort="Peacock Hinton, Sharon" uniqKey="Peacock Hinton S" first="Sharon" last="Peacock Hinton">Sharon Peacock Hinton</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001181 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001181 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:4966516 |texte= Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27069085" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |